Alternative data can take on different meanings to investors so let’s start with a general definition: “alt” data refers to non-traditional or unique information not previously known or available to financial markets.
On March 14, 2019, data partner Lucena Research co-hosted a panel discussion with Wall Street Horizon. The event “Finding Tradable Signals in Alt Data” featured the following panel:
The scheduling of corporate events such as earnings release dates can point to significant, untapped sources of alpha, as firm-initiated revisions to expected earnings announcement dates are strong predictors of firms’ upcoming earnings news.
While we have seen a dramatic rise of virtual shareholder meetings over the past few years, there has also been an increase of in-person attendance at investor conferences putting the competing ‘virtual vs. human’ views at odds. We take a closer look, below.
Those who trade off of corporate events know that when a company delays the release of their earnings it’s typically because there is bad news to report.
An IRO’s job is to provide bi-directional visibility. They give their management teams visibility into what the financial community thinks about how their companies are being run both individually and as compared to others in their sectors. Ultimately it is those perceptions that affect their stock prices. Conversely, the IRO has groups to service – shareholders, analysts and other financial constituents – for whom they provide visibility into their companies’ strategies, operations and performance.
Publicly traded companies are scrutinized more than ever today. Information about them is dissected and fed into investors’ models and trading strategies the instant it becomes available. When signals are detected, they trigger actions, often in microseconds. So having better information sooner is the name of the game.
A recent article from CNBC shows that asset managers and hedge funds are becoming increasingly reluctant to pay for analyst research reports that they once relied on so heavily. In fact, data shows a 25% decrease from client spend on reports compared to a year earlier. While the importance and need for in-depth research and insight is by no means diminishing, the means in which traders are consuming and obtaining analyst intelligence is changing in a somewhat surprising way.
Looking for accurate, comprehensive event data to stay on top of volatility? Wall Street Horizon has the unique tools and the research to support the importance of corporate events relative to volatility.
With the strong comeback of the biotech sector in 2017, now is as good a time as any to consider the corporate event data that can affect volatility. Although event data can range from FDA drug approval dates and FDA Advisory Committee meetings to investor conferences and analyst days, in this post, I’d like to focus on FDA drug approval dates.